Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin swabs could reveal hidden signals of incontinence rash

NCT ID NCT07816549

Diagnosis Sponsor: Essity Hygiene and Health AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are studying whether skin swabs can show measurable differences between skin affected by incontinence-associated dermatitis and unaffected skin. The study enrolls adults who use incontinence products regularly and have an area of affected skin. By comparing biomarkers from both areas, the team aims to find signals that could help identify this common skin condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers find reliable biomarker patterns, doctors could one day identify incontinence-associated dermatitis earlier or tell it apart from other skin problems more easily.
What could go wrong
This is a small exploratory study of 10 people, so any biomarker patterns it finds may not hold up in larger groups or lead to a usable test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

10 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is individuals with incontinence that wear an absorbing incontinence product and has the signs of incontinence associated dermatitis (IAD).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. Age ≥ 18 years. 2. Mentally and physically able to participate in this study. 3. Willing and able to provide written informed consent to participate in this study or, if unable to provide such consent, have a legal representative who is willing and able to provide informed consent on behalf of the participant. 4. Individual with urinary and/or faecal incontinence and using incontinence products at a regular basis. 5. Has an area under incontinence products with IAD, incontinence associated dermatitis that shows any sign(s) of skin irritation e.g., redness, itching, rashes. 1A and 2A according to GLOBIAD categorisation model \[Appendix C for detailed description\]. 1A is persistent redness without clinical sign of infection and 2A is skin loss without clinical sign of infection. Exclusion criteria 1. Severe skin breakdown at the investigated area. 2. Individual with skin infection at the investigated area. 3. GLOBIAD 1B and 2B, 1B is persistent redness with clinical signs of infection and 2B is skin loss with clinical sign of infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Incontinence-associated dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Incontinence-associated dermatitis

Contacts and locations

Locations

  • Nursing home

    Mölndal, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.